Advagene Biopharma Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was TWD 118.38 million compared to TWD 92.69 million a year ago. Basic loss per share from continuing operations was TWD 2.4 compared to TWD 1.9 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.2 TWD | +0.45% | -3.06% | -12.60% |
1st Jan change | Capi. | |
---|---|---|
-12.60% | 36.5M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- 6709 Stock
- News Advagene Biopharma Co., Ltd.
- Advagene Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022